330 related articles for article (PubMed ID: 15045710)
21. Treatment with rituximab in benign and malignant hematologic disorders in children.
Giulino LB; Bussel JB; Neufeld EJ;
J Pediatr; 2007 Apr; 150(4):338-44, 344.e1. PubMed ID: 17382107
[No Abstract] [Full Text] [Related]
22. [Molecular targeted treatment of hematological diseases with monoclonal antibodies and tyrosine kinase inhibitors. The Danish Society of Hematology].
Geisler CH
Ugeskr Laeger; 2002 Mar; 164(12):1655. PubMed ID: 11924277
[No Abstract] [Full Text] [Related]
23. Rituximab in refractory autoimmune bullous diseases.
Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody as therapy for malignant lymphomas.
Coiffier B
C R Biol; 2006 Apr; 329(4):241-54. PubMed ID: 16644494
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in autoimmune diseases.
Virgolini L; Marzocchi V
Biomed Pharmacother; 2004 Jun; 58(5):299-309. PubMed ID: 15194166
[TBL] [Abstract][Full Text] [Related]
26. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
28. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
Kazkaz H; Isenberg D
Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
[TBL] [Abstract][Full Text] [Related]
29. [Future directions of antibody therapy].
Oguro M
Nihon Rinsho; 2007 Jan; 65 Suppl 1():629-36. PubMed ID: 17474471
[No Abstract] [Full Text] [Related]
30. Cytomegalovirus gastritis after treatment with rituximab.
Hasegawa Y; Goto A; Nishimura S; Sukawa Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Shinomura Y; Yoshida Y
Endoscopy; 2009; 41 Suppl 2():E199. PubMed ID: 19637127
[No Abstract] [Full Text] [Related]
31. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
32. Risk factors for infection in haematology patients treated with rituximab.
Kanbayashi Y; Nomura K; Fujimoto Y; Yamashita M; Ohshiro M; Okamoto K; Matsumoto Y; Horiike S; Takagi T; Ishida Y; Taniwaki M;
Eur J Haematol; 2009 Jan; 82(1):26-30. PubMed ID: 19018858
[TBL] [Abstract][Full Text] [Related]
33. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
34. CD20: a target antigen for immunotherapy of autoimmune diseases.
Perosa F; Favoino E; Caragnano MA; Prete M; Dammacco F
Autoimmun Rev; 2005 Nov; 4(8):526-31. PubMed ID: 16214090
[TBL] [Abstract][Full Text] [Related]
35. [Bacteremia in hematological malignant disorders].
Hammerstrøm J; Røym AL; Gran FW
Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1655-9. PubMed ID: 18704131
[TBL] [Abstract][Full Text] [Related]
36. [Antibody therapy in hematology and oncology--2].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2009 Jan; 104(1):28-49. PubMed ID: 19142594
[No Abstract] [Full Text] [Related]
37. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
38. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Aurer I; Mitrović Z; Radman I; Kovacević-Metelko J; Nemet D; Serventi-Seiwerth R; Stern-Padovan R; Jakic-Razumović J; Nola M; Zupancić-Salek S; Sertić D; Labar B
Lijec Vjesn; 2004; 126(11-12):307-11. PubMed ID: 16082888
[TBL] [Abstract][Full Text] [Related]
39. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
40. London's disastrous drug trial has serious side effects for research.
Wadman M
Nature; 2006 Mar; 440(7083):388-9. PubMed ID: 16554763
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
